J P Morgan Chase & Co set a GBX 4,500 ($59.79) target price on AstraZeneca plc (LON:AZN) in a research report released on Wednesday. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

AZN has been the topic of several other reports. HSBC Holdings plc reiterated a reduce rating and issued a GBX 4,100 ($54.48) price target on shares of AstraZeneca plc in a research note on Monday, September 11th. Barclays PLC reiterated an overweight rating and issued a GBX 6,300 ($83.71) price target on shares of AstraZeneca plc in a research note on Thursday, October 5th. UBS AG set a GBX 5,150 ($68.43) price target on shares of AstraZeneca plc and gave the company a neutral rating in a research note on Tuesday, June 27th. BNP Paribas set a GBX 5,300 ($70.42) price target on shares of AstraZeneca plc and gave the company a neutral rating in a research note on Monday, September 11th. Finally, Citigroup Inc. reiterated a buy rating and issued a GBX 6,000 ($79.72) price target on shares of AstraZeneca plc in a research note on Friday, July 28th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of GBX 5,172.64 ($68.73).

Shares of AstraZeneca plc (AZN) traded down 0.02% during midday trading on Wednesday, reaching GBX 5175.00. 2,555,117 shares of the company were exchanged. The company’s market capitalization is GBX 65.52 billion. The stock has a 50-day moving average price of GBX 4,904.35 and a 200 day moving average price of GBX 4,912.64. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00.

ILLEGAL ACTIVITY WARNING: “AstraZeneca plc (AZN) Given a GBX 4,500 Price Target at J P Morgan Chase & Co” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/astrazeneca-plc-azn-given-a-gbx-4500-price-target-at-j-p-morgan-chase-co/1641648.html.

In other news, insider Nazneen Rahman bought 39 shares of the company’s stock in a transaction dated Thursday, July 27th. The stock was bought at an average cost of GBX 4,370 ($58.07) per share, for a total transaction of £1,704.30 ($2,264.55).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.